Literature DB >> 25616633

In reply to 'discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome'.

Gianluigi Ardissino1, Ilaria Possenti1, Francesca Tel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25616633     DOI： 10.1053/j.ajkd.2014.05.028

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  2 in total

1.  Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update.

Authors:  Gianluigi Ardissino; Francesca Tel; Martina Sgarbanti; Donata Cresseri; Antenore Giussani; Samantha Griffini; Elena Grovetto; Ilaria Possenti; Michela Perrone; Sara Testa; Fabio Paglialonga; Piergiorgio Messa; Massimo Cugno
Journal:  Pediatr Nephrol       Date:  2017-10-18       Impact factor: 3.714

Review 2.  C3 glomerulopathy and atypical hemolytic uremic syndrome: an updated review of the literature on alternative complement pathway disorders.

Authors:  Kultigin Turkmen; Ismail Baloglu; Hakan Ozer
Journal:  Int Urol Nephrol       Date:  2021-01-03       Impact factor: 2.370
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.